SCHEMBL28136231

SCHEMBL28136231

CCCc1cc(CCC)c(-c2ccccc2)c(CCC)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ALOX5 P09917 1/20 0.38
NPC1 O15118 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CTSK P43235 1/20 0.36
TSHR P16473 1/20 0.35
SREBF2 Q12772 1/20 0.35
TP53 P04637 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
HSD11B1 P28845 1/20 0.34
DHFR P00374 1/20 0.34
CHRM1 P11229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27747966 0.84 TAAR1 (0.50) MAPTKDM4EALDH1A1HSD17B10NPC1
SCHEMBL2094991 0.82 DHFR (0.47) KDM4EALDH1A1HSD17B10TP53HSD11B1
SCHEMBL1369568 0.81 ALOX5 (0.36) MAPTALDH1A1ALOX5CNR1CNR2
SCHEMBL28173019 0.79 MAPT (0.42) MAPTKDM4EALDH1A1HSD17B10HPGD
SCHEMBL31398721 0.78 HSD17B10 (0.40) MAPTKDM4EALDH1A1HSD17B10NPC1
SCHEMBL4228936 0.74 CNR1 (0.34) ALOX5CNR1CNR2
SCHEMBL7120971 0.74 HSD11B1 (0.44) HPGDCNR1CNR2HSD11B1
SCHEMBL1370284 0.73 ALOX5 (0.30) ALOX5CNR1CNR2
SCHEMBL19785365 0.73 ALOX5 (0.40) ALOX5CNR1CNR2HSD11B1
SCHEMBL30585175 0.72 RARB (0.44) MAPTALDH1A1HSD17B10NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034126-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-02-05 US disclosed
CN-106133604-B Protectant composition and protectant pattern forming method 三菱瓦斯化学株式会社 2019-09-06 CN disclosed
CN-109311844-A Triaizine compounds, its manufacturing method and the organic electroluminescent device as constituent 东曹株式会社 2019-02-05 CN disclosed
CN-104281006-B Radiation-ray sensitive composition 三菱瓦斯化学株式会社 2019-01-22 CN disclosed
CN-109073782-A Optical element forms composition and its solidfied material 三菱瓦斯化学株式会社 2018-12-21 CN disclosed
CN-105308026-B Cyclic azine compound, manufacturing method with adamantyl and using the compound as the organic electroluminescent device of constituent 东曹株式会社 2018-12-21 CN disclosed
CN-106232592-B Triazine compound and method for producing same 东曹株式会社 2018-12-21 CN disclosed
CN-106573912-A Triazine compound, method for producing same, and application for same 东曹株式会社 2017-04-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034126-A1 KRAS INHIBITORS KRAS, NRAS, HRAS MAPT 4877/4885KDM4E 4263/4885ALDH1A1 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.